Register Login

Scholar Rock Holding Corp (SRRK)

  • Event
  • June 17, 2022, 11:15 UTC

(90% Positive) Scholar Rock Holding Corporation (SRRK) Announces Enrollment Update for apitegromab Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 8:02 a.m.

    📋 Scholar Rock Holding Corporation (SRRK) - Clinical Trial Update

    Filing Date: 2022-06-17

    Accepted: 2022-06-17 07:15:28

    Event Type: Clinical Trial Update

    Event Details:

    Scholar Rock Holding Corp (SRRK) Announces Clinical Trial Update Scholar Rock Holding Corp (SRRK) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: apitegromab
    • Clinical Stage: Phase 3, Phase 2
    • Collaboration: Revised Upper Limb Module
      • targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/). Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Scholar Rock Holding Corp
    • CIK: 0001727196
    • Ticker Symbol: SRRK
    • Period End Date: 2022-06-17
    • Document Type: 8-K

Search

News categories